Spinal muscular atrophy care in the COVID-19 pandemic era.
Muscle Nerve
; 62(1): 46-49, 2020 07.
Article
in English
| MEDLINE | ID: covidwho-116283
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic has resulted in reorganization of healthcare settings affecting the delivery of clinical care to patients with spinal muscular atrophy (SMA). There is a concern that patients with SMA may be at increased risk of manifesting severe symptoms of COVID-19. Currently approved therapies for SMA improve survival and motor function; however, their delivery requires an increased exposure to the health system and a dedicated healthcare team. In this study, we discuss consensus recommendations pertaining to care of SMA patients during the pandemic. We highlight that SMA treatments should not be perceived as elective. Decisions regarding the delay of treatments should be made with consideration of the potential risks of COVID-19 exposure and the risk of that delay. We emphasize the importance of collaborative treatment decisions between the patient, family, and healthcare provider, considering any geographic- or institution-specific policies and precautions for COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Muscular Atrophy, Spinal
/
Coronavirus Infections
/
Disease Management
/
Delivery of Health Care
/
Consensus
/
Pandemics
/
Betacoronavirus
Type of study:
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Muscle Nerve
Year:
2020
Document Type:
Article
Affiliation country:
Mus.26903
Similar
MEDLINE
...
LILACS
LIS